{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:50:26Z","timestamp":1795175426192,"version":"4.10.3"},"reference-count":22,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T00:00:00Z","timestamp":1205107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:sec><jats:title>AIMS<\/jats:title><jats:p>To assess the effect of maraviroc on the pharmacokinetics of midazolam, a sensitive probe CYP3A4 substrate; lamivudine\/zidovudine, a combination of nucleoside reverse transcriptase inhibitors (NRTIs); and ethinyloestradiol\/levonorgestrel, a combination oral contraceptive.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Three randomized, double\u2010blind, placebo\u2010controlled studies were conducted in healthy subjects to assess the effect of maraviroc on pharmacokinetics of other drugs. Two, two\u2010period crossover studies were conducted to assess (i) the effect of steady\u2010state maraviroc (300\u2003mg b.i.d.) on pharmacokinetics of midazolam; and (ii) the effect of steady\u2010state maraviroc (300\u2003mg b.i.d.) on the pharmacokinetics of lamivudine\/zidovudine. A third two\u2010way crossover study was conducted to evaluate the effect of steady\u2010state maraviroc (100\u2003mg b.i.d.) on the pharmacokinetics of 30\u2003\u03bcg ethinyloestradiol\/150\u2003\u03bcg levonorgestrel (Microgynon\u00ae).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The geometric mean ratios for <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and AUC for each of the compounds tested in the presence and absence of maraviroc were between 92% and 121%. There were no notable differences in <jats:italic>T<\/jats:italic><jats:sub>max<\/jats:sub>, <jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub> or CL<jats:sub><jats:italic>R<\/jats:italic><\/jats:sub> (where measured) for any of the compounds.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Maraviroc had no clinically relevant effects on the pharmacokinetics of the CYP3A4 substrate midazolam, the NRTIs zidovudine\/lamivudine, or the oral contraceptive steroids ethinyloestradiol and levonorgestrel.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2008.03132.x","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T04:04:35Z","timestamp":1205208275000},"page":"19-26","source":"Crossref","is-referenced-by-count":48,"title":["Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine\/ zidovudine, and ethinyloestradiol\/ levonorgestrel in healthy volunteers"],"prefix":"10.1111","volume":"65","author":[{"given":"Samantha","family":"Abel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsey A.","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E.","family":"Ridgway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Muirhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.104609"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.60"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004266783"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.2.251"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809703100915"},{"key":"e_1_2_6_7_2","unstructured":"HylandR JonesB MuirheadG.In vitroassessment of the CYP\u2010based drug\u2013drug interaction potential of UK\u2010427\u2003857. In: 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 April 1\u20133; Rome Italy."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03130.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03137.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389200043335450"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.082826"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199212000-00008"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.125"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90183-6"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.176"},{"key":"e_1_2_6_16_2","first-page":"649","article-title":"Human bilirubin UDP\u2010glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol","volume":"43","author":"Ebner T","year":"1993","journal-title":"Mol Pharmacol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.000182"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvi047"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qco.0000200295.30285.13"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-006-0037-1"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1055329002250993"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00749.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309011-00003"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2008.03132.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2008.03132.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T14:27:13Z","timestamp":1694615233000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2008.03132.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,10]]},"references-count":22,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1365-2125.2008.03132.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03132.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,10]]}}}